Bank of America
MRTX

Bank of America’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bank of America’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-490,000
Closed -$34.2M – 8523
2022
Q3 		$34.2M Buy
+490,000
New +$36.3M ﹤0.01% 1551
2021
Q4 		– Sell
-9,400
Closed -$1.66M – 8809
2021
Q3 		$1.66M Buy
9,400
+7,600
+422% +$1.22M ﹤0.01% 4608
2021
Q2 		$291K Buy
1,800
+1,200
+200% +$193K ﹤0.01% 5821
2021
Q1 		$103K Buy
+600
New +$119K ﹤0.01% 6377

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's MRTX Position: Q1 2024 in Review

Bank of America sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 36,000 shares — an estimated $2.11M sold.

Bank of America first reported a position in MRTX in Q2 2014 and held it in 37 quarters. The position peaked at $35.1M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Bank of America reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of America sold 36,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.11M.
  • Bank of America first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 37 quarters.
  • Bank of America's Mirati Therapeutics, Inc. Common Stock position peaked at $35.1M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.